The White House has decided to terminate Marty Makary’s tenure as Commissioner of the U.S. Food and Drug Administration (FDA), according to sources familiar with the matter. In a swift move to ensure continuity at the federal health regulator, the administration is reportedly preparing to name Kyle Diamantas, the current FDA Deputy Commissioner overseeing the agency’s food group, as acting head, Reuters has reported.
The decision represents the latest significant leadership shake-up within the Department of Health and Human Services, signaling a shift in the administration’s strategic direction for public health oversight.
A Sudden Departure from the Helm
The move to fire Makary follows internal deliberations at the White House, with three sources confirming that the plan for his removal has been formally approved. While the specific reasons for the dismissal remain undisclosed, the departure of a sitting FDA Commissioner often indicates a desire for a change in policy pace or a realignment of the agency’s priorities with executive branch goals.
Makary, a prominent figure in the medical community, has led the agency through a complex period of regulatory scrutiny. However, it appears the administration is now seeking a fresh perspective to steer the organization forward.
Internal Promotion to Ensure Stability
To fill the leadership gap, the White House is expected to turn to Kyle Diamantas, a seasoned official within the FDA’s internal ranks. Currently serving as Deputy Commissioner with a focus on the agency’s food group, Diamantas is viewed as a reliable choice capable of managing the transition.
His deep familiarity with the FDA’s bureaucratic structure and his recent work on food safety and nutrition policy make him the primary candidate for the acting role. If confirmed, his appointment will be tasked with maintaining momentum on ongoing drug approvals and food safety inspections while a permanent successor is sought.
